BioPharmSignal logoBioPharmSignal

Biotech News

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Exagen (XGN)ExagenEarnings

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.

Related news

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

INMBINmune Bio2026-07-31 11:00 EST

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

MDXHMDxHealth2026-07-30 20:00 EST

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SERASera Prognostics2026-07-29 20:05 EST

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

BDSXBiodesix2026-07-22 10:00 EST

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

View all latest news

Exagen

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

XGNExagen2026-06-01 13:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close
6.59 USD
Market cap
116.45M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States